|
09 Jan 2020 |
Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
|
|
08 Jan 2020 |
Promethera announces Initiation of Phase 2b DHELIVER Study of HepaStem™ in patients with Acute-on-Chronic Liver Failure (ACLF)
|
|
06 Jan 2020 |
Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer
|
|
03 Jan 2020 |
BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science
|
|
02 Jan 2020 |
Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
|
|
30 Dec 2019 |
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
|
|
26 Dec 2019 |
Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
|
|
23 Dec 2019 |
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
|
|
23 Dec 2019 |
Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
|
|
21 Dec 2019 |
Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer's Disease
|
|
21 Dec 2019 |
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
|
20 Dec 2019 |
Solid Biosciences Provides Data Update from SGT-001 Development Program
|
|
20 Dec 2019 |
Akcea Retains Rights to AKCEA-APOCIII-LRx
|
|
20 Dec 2019 |
NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
|
|
20 Dec 2019 |
Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis
|
|
20 Dec 2019 |
Clinical trial application for pivotal JTA-004 Phase III study submitted
|
|
20 Dec 2019 |
REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)
|
|
19 Dec 2019 |
Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
|
|
18 Dec 2019 |
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU
|
|
17 Dec 2019 |
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
|
|
16 Dec 2019 |
Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
|
|
16 Dec 2019 |
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS
|
|
16 Dec 2019 |
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
|
|
16 Dec 2019 |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
|
|
16 Dec 2019 |
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
|
